Recent clinical data for approaches targeting mTORC1, mTORC2 and PI3K (e.g. sapanisertib/serabelisib which target mTORC1, mTORC2 and PI3Kα, or pan-PI3K/mTOR inhibitor gedatolisib) have shown promising efficacy signals in cancer patients, suggesting that combined mTORC1/2 and PI3K inhibition may be the preferable MNI strategy [22–25]. This evidence concerns the gene PIK3CG and cancer.